Moderna posts reported net loss of $3.6bn in Q3 earnings
Revenues saw a 32% decline to $3.4bn from $5bn in the same quarter of the previous year, but the company is projecting a profit in 2024.
03 November 2023
03 November 2023
Revenues saw a 32% decline to $3.4bn from $5bn in the same quarter of the previous year, but the company is projecting a profit in 2024.
As per the latest restructuring plan, Sangamo will advance its programs using AAV capsid delivery, Nav1.7 program, and Prion therapies.
The company terminated the RT-101 programme while pausing the development of the RT-105 and RT-110 compounds.
The latest approval for RYEQO is applicable in all European Union member states.
A 37% surge in worldwide revenue to $9.5bn was reported, versus $6.9bn in Q3 2022.
The companies will jointly develop up to five antibody-drug conjugates for treating cancer, with a focus on SMARCA degraders.
Memo’s fast track-designated candidate is currently in a Phase II trial for BKV infection, with a data readout expected in 2024.
The rapid rollout of direct oral anticoagulants has prevented an estimated 17,000 strokes and 4,000 deaths, says the NHS.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Despite challenging business conditions in 2021 and 2022, large CMOs were still involved in acquisitions to enhance their capabilities or scale of production. Catalent and Recipharm were particularly active in acquiring companies during this period, and these acquisitions had a focus on advanced biologic capabilities related to cell and gene therapies. CMOs are increasingly targeting companies with sophisticated (biologic and specialized) capabilities to manufacture modern drugs and seek high-value contracts.
Give your business an edge with our leading industry insights.